GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) YoY EBITDA Growth: 15.04% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
78 GF Score
Price ₹2,828.40
GF Value ₹2,741.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals YoY EBITDA Growth?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO -0.44% 78 YoY EBITDA Growth is 15.04% as of Jun. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 78/100 and a GF Value™ of ₹2,741.89 (Fairly Valued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. GlaxoSmithKline Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 15.04%.

GlaxoSmithKline Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2026 was ₹20.03.

GlaxoSmithKline Pharmaceuticals YoY EBITDA Growth Related Terms

GlaxoSmithKline Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals YoY EBITDA Growth Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.40 6.45 -1.80 49.60 11.08

GlaxoSmithKline Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.82 3.02 28.88 3.45 15.04
NSE:GLAXO
78GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

GlaxoSmithKline Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(87.08-78.391)/ | 78.391 |
=11.08 %

GlaxoSmithKline Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(20.025-17.407)/ | 17.407 |
=15.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 15.04% mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a YoY EBITDA Growth of 15.04% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' YoY EBITDA Growth too high?
GlaxoSmithKline Pharmaceuticals' current YoY EBITDA Growth is 15.04%. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' YoY EBITDA Growth compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' YoY EBITDA Growth of 15.04% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current YoY EBITDA Growth is 15.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,741.89, compared to a current price of ₹2,828.40 — trading 3.2% above its estimated fair value. The current YoY EBITDA Growth is 15.04%. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current YoY EBITDA Growth is 15.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,828.40 is trading 3.2% above its estimated GF Value™ of ₹2,741.89. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • YoY EBITDA Growth: 15.04%
  • GF Value™: ₹2,741.89 vs. price of ₹2,828.40 (3.2% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
78GF Score

Get the complete analysis for NSE:GLAXO

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,828.40
Price
₹2,741.89
GF Value